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ABSTRACT 
 
Background: Pharmacovigilance is the “science and activities relating to the detection, assessment, 
understanding and prevention of adverse effects or any other drug related problems”. The most 
commonly used adverse drug reaction (ADR) reporting system worldwide is spontaneous and voluntary 
reporting, which forms the backbone of reporting systems. Aims: To explore the current status of 
consumer involvement in the pharmacovigilance program in three developing countries, Yemen, Nepal 
and Malaysia. Method: An analysis was carried out for these three countries based on the current status 
of pharmacovigilance and involvement of consumers in their pharmacovigilance programs.   
Results: Malaysia has a good system for involving consumers in their national pharmacovigilance 
system, whereas Yemen still lacks the well-formed national drug policy. Lack of legislation and 
regulation which govern the import and distribution of drugs in Yemen is a limiting factor for 
development of consumer pharmacovigilance. Despite establishment of a pharmacovigilance centre, no 
reports have been released by the centre. The status of pharmacovigilance in Nepal is still in infancy. 
The regulatory body is assigned to be a national pharmacovigilance center, and coordinates with seven 
regional centers for pharmacovigilance activities. Nepal also lacks the involvement of consumers in the 
national pharmacovigilance program. Conclusion: Consumer reporting may be important for developing 
countries to implement a proper and effective pharmacovigilance program that can reduce morbidity and 
mortality rates, as well as reducing the economic burden of ADRs. 
 
Introduction 
 
In the past few decades, there has been an exponential growth in 
the global human population. Improved patient care and better 
medicines to treat diseases have played a pivotal role in extending 
human lifespan and reducing morbidity. However, medicines 
could also be potentially hazardous. Recipients of prescribed 
drugs or medicines may expose themselves to Adverse Drug 
Reactions (ADRs) which have been identified as one of the 
leading cause of hospitalization and may lead to morbidity and 
mortality. This leads to pain or suffering among recipients and 
also causes economic burden.[1] 
 
One of the earliest definitions for Adverse Drug Reaction was 
established by the World Health Organization which reads as: 
“……any response to a drug which is noxious, unintended and 
occurs at doses used in man for prophylaxis, diagnosis or therapy 
of disease or modification of physiological function.”[2] 
 
Quite recently, addressing the absence of the patient’s perspective 
found in the previous definition, Edwards and Aronson propose 
the following definition:“……an appreciably harmful or 
unpleasant reaction resulting from the use of  a  medicinal  
product,  which  predicts  hazard  for  future  administration  and 
warrants prevention or specific treatment, alteration of the 
dosage regimen or  withdrawal of the product.”[3] 
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The field of drug safety or pharmacovigilance has attracted 
serious attention and focus especially during the last ten years. 
This is evident from the increased number of publications 
addressing post-marketing drug-related events in scientific 
journals globally. Originally, 10 countries contributed 
information to the international system for monitoring ADRs.  At 
present, the number of contributing countries has reached 113; 
Malaysia and Nepal are members of the WHO drug monitoring 
program. 
 
The most commonly used ADR reporting system worldwide is 
spontaneous and voluntary reporting. However, significant under-
reporting of ADRs by healthcare professionals has been identified 
as a serious drawback of the voluntary reporting system and is 
prevalent in various countries.[4] There are many previous studies 
which underline the importance of ADR reporting. The 
motivation behind the establishment of the ADR reporting system 
is the fact that ADRs are common, yet preventable causes of 
illness and disability. ADRs are ranked as the top 10 causes of 
mortality in the United States of America (USA), United 
Kingdom (UK) and Europe. For instance, 6.5% of all hospital 
admissions in the UK were caused by ADRs. In terms of the 
economic burden, this is equivalent to £466 million annually. [5] 
Hence, establishing a well-organized and efficient 
pharmacovigilance system to evaluate and monitor the safety of 
medicines in clinical use is crucial. 
The current system of reporting depends on spontaneous  reports 
submitted by doctors and pharmacists. Involvement of consumers 
in ADR reporting can reinforce their rights and ensure the safer 
use of medicines in future. Consumers‘ experiences and views 
can provide additional information about ADRs. ADR reporting 
by consumers has been possible for almost 15 years in developed 
countries. However, only a few countries currently accept patient 
reports. Countries like Sweden started consumer reporting for 
ADRs in 1978 and the USA followed in 1993. Denmark started 
consumer reporting in 2003, Canada  and Australia started in 
2003 the Netherlands in 2004, and the UK in 2005. [1]   
In Europe and the United States there is now over two decades of 
experience regarding consumer ADR reporting. A study done to 
investigate the relative contribution of patient reporting to signal 
detection in the UK showed that patient reporting may provide a 
positive complementary contribution to the reports received from 
health care practitioners (HCPs). [5] Similarly, another study 
indicated that free text comments often contained in case reports 
directly submitted by patients can be of value 
in pharmacovigilance and provide important information on 
how a drug may affect the person using it and the influence 
it may have on his or her personal life. [6] 
An 11 country survey of the methods of patient reporting of 
ADRs revealed the importance of giving the public the 
opportunity to report ADRs and the additional value of 
patient reports. Most countries have three different ways 
for patients to report ADRs - a paper form, an electronic 
form on a website or by telephone. The route of handling of 
patients' and HCPs' ADR reports is the same for most 
countries. The Netherlands and the Uk are actively 
evaluating their patient reporting systems.  
Less than 3% of reports added to the WHO database in the 
year 2000 originated from developing countries, although 
around 80% of the global population lives in the developing 
world. Developing countries have an urgent need to improve their 
pharmacovigialnce systems. Hence, consumer reporting is hghly 
aceptable and should be ecouraged from the developing countries. 
[8,9]  
 
Pharmacovigilance in Yemen 
 
In Yemen health services particularly hospitals and private health 
facilities are concentrated in major cities. Primary health units 
and centres as well as polyclinics are scattered throughout the 
country. The local pharmaceutical industry is growing at a slow 
rate and most of the country’s needs are catered to by imports. 
ADR reporting systems do not cover the whole country and there 
is lack of a systematic plan to monitor drug reactions and related 
problems. A pharmacovigilance center was established in 2011 by 
the Supreme Board of Drugs and Medical Appliances(SBDMA). 
However, there are no official data or reports released by the 
SBDMA on the number of ADRs being reported and how they 
are being processed [10].  There is no provision for collecting and 
disseminating information about ADRs. The centre is located in 
the capital city and has no systematic contact with other 
governorates.   Neither health care providers nor medicine 
consumers are aware about the centre. Therefore it can be 
concluded that there is little involvement of both health 
professionals and the public in the national pharmacovigilance 
program. 
Pharmacovigilance in Nepal 
 
The Ministry of Health and Population, Department of Drug 
Administration (DDA) was established in Nepal as per the Drug 
Act 1978.  It is responsible for the manufacture, import/export, 
sales, distribution and storage of drugs in Nepal. DDA is also the 
National Center for Phamacovigilance.  Pharmacovigilance was 
initiated in Nepal in 2004 and the country became a member of 
the International Pharmacovigilance Program in 2007.[11] The 
national pharmacovigilance center coordinates with seven 
regional centers in Nepal among which five are situated in the 
capital of the country while two are located in the eastern and 
western region of Nepal. These centers collect ADR reports from 
health care professionals and forward them to the Department of 
Drug Administration (DDA) from where the reports are sent to 
the Uppsala Monitoring Centre in Sweden, a centre for 
international service and scientific research towards patient 
safety. [12] 
 
A national ADR reporting form is available through the DDA’s 
website, and other regional centers have developed their own 
forms. But, many of the stakeholders within as well as outside the 
regional pharmacovigilance centers are not yet aware of the form 
and its intended use as a reporting mechanism for suspected 
ADRs. The collected ADRs are reported to the national center 
through a database system known as ‘Vigibase’. There are very 
few ADRs which have been reported to the national center till 
date. There is a lack of a system for disseminating information 
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about the types of reactions reported to the DDA and no 
provisions for reporting by consumers in the pharmacovigilance 
program in Nepal. The whole program is still in the developing 
stage and is only 10 years old in Nepal. 
 
Pharmacovigilance in Malaysia 
 
In Malaysia, spontaneous, voluntary ADR reporting is the most 
commonly used method, and the program is monitored by the 
National Adverse Drug Monitoring Center. The ADR reporting 
system covers the entire country and some major hospitals and 
pharmaceutical companies have been running ADR monitoring 
systems.[1] Even though the monitoring system has been running 
for more than 20 years, the quantity of reports, especially from 
the community of pharmacists remains low, compared to other 
countries.[13] 
 
Malaysia has a well established national centre of 
pharmacovigilance, namely the National Adverse Drug Reaction 
Monitoring Centre. Some major hospitals and pharmaceutical 
companies also operate ADR monitoring systems under the 
national centre. ADRscan be reported either directly to the 
national center or through hospitals and pharmaceutical 
companies that run pharmacovigilance programs. Reports are 
then consolidated at the national center. Reports from doctors, 
pharmacists and dentists are made on a voluntary basis but reports 
from pharmaceutical industry are mandatory. The centre monitors 
drugs for human use, vaccines, biological and herbal remedies, 
using prepaid postage report forms or report cards. It also records 
ADRs manually, and has a local database. The national centre has 
an advisory committee that assesses the causality of the reported 
ADRs.[1] The Malaysian Adverse Drug Reaction Advisory 
Committee (MADRAC) was established under the Drug Control 
Authority (DCA) to monitor the safety profiles of drugs registered 
for use in Malaysia. MADRAC provides DCA with information 
pertaining to drug safety issues occurring locally and 
internationally. The National Drug Safety Monitoring Centre, 
which is the secretariat of MADRAC, was accepted as the 30th 
member of the WHO Safety Monitoring Program in 1990. Under 
this program, all ADR reports that have been received and 
screened by MADRAC are submitted to the Uppsala Monitoring 
Centre in Sweden for inclusion in the WHO database.  
MADRAC also promotes ADR reporting in Malaysia, and 
provides information and advice to the DCA so that regulatory 
action can be taken based on the ADRs received. It also provides 
information to doctors, pharmacists and other healthcare 
professionals on ADRs and participates in the WHO ADR 
monitoring program.  A total of 7079 reports were received in 
the year 2010 which is in tune with the increasing trend every 
year.  This figure is a 21% increase from the year 2009. Of the 
7079 reports received, 5976 reports (84.4%) were sent in by 
healthcare professionals from the government sector. This is an 
increase from the previous year’s 4698 reports from the 
government sector. The year 2010 also showed an increase 
(72.2%) in the number of ADR reports from private healthcare 
professionals(248 reports) compared to 2009 (144 reports). 
However, reports from Marketing Authorisation Holders (MAH) 
saw a decreasing trend since the year 2008. There was also an 
increase in the number of reports from the ‘Others’ category of 
reporters due to the higher number of reports submitted by 
nurses (338 reports) in accordance with the Human 
Papillomavirus (HPV)national immunisation programme. Only 
7 reports were submitted by consumers.[14] Table 1 compares 
different facts and figures for the three countries, Yemen, Nepal 
and Malaysia. 
  
Table1: Characteristics of Malaysian, Nepali and Yemeni health care systems 
Key figures Malaysia* Nepal** Yemen*** 
Population  29.7 million 30.5 million 25 million 
GDP 
 
USD 9,977.32 
per capita 
USD 619 per capita USD 659 per capita 
Health Expenditure (%GDP) 4.9  6.33 5.3 
Practicing physicians 36,607 14,059 7,629 
Practicing dentists 4,253 950 329 
Practicing pharmacists 8,632 1311 1,024 
Year when pharmacovigilance 
activities were started 
1983 2004 2011 
No. of total  ADRs reports in 
2010 
7079 523 No data 
Year when consumer reporting 
was initiated  
2007 Not yet started 2011 
Source: *Malaysian Health Fact 2012.  : http://www.moh.gov.my/images/gallery/stats/heal_fact/health_fact_2012_page_by_page.pdf 
**Ministry of Public Health & Population of the Republic of Yemen, in collaboration with the World Health Organization. (2012). 
Yemen Pharmaceutical Country Profile. 
***Department of Health Services: Annual report F/Y 2009/10.Government of Nepal, Kathmandu; 2011. 
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Benefits of incorporating consumers in ADR reporting 
systems 
 
Most ADR reporting systems in the world have focused 
heavily on spontaneous and voluntary reporting. National 
pharmacovigilance initiatives in most countries have suffered 
from under-reporting.[15]Self-medication is common in most 
developing countries. Inappropriate use of medicines and 
ADRs could have originated from commercial advertising 
which promotes self-medication Consumers/patients could 
well be an important source of ADR reporting since in 
principle, they have a vested interest in reporting ADRs. 
 
One of the first countries that allowed ADR reporting by 
consumers was the United States. The initiative started as 
early as the 1960s and consumers had the opportunity to report 
ADRs directly to the Food and Drug Administration (FDA). 
Since 2003, consumers in the Netherlands have the 
opportunity to report possible ADRs to a foundation, separate 
from the country’s national drug regulatory authority known 
as LAREB. In the same year, patients in Denmark were 
offered a similar opportunity, followed by Italy in 2004, the 
UK and Sweden in 2008 and Norway in 2013. In a survey 
conducted in three states of India involving 566 households, 
the author concluded that there was an increasing trend of 
involving consumers in the process of health care. Advantages 
of consumer reporting include better quality of ADR reports, 
increase in number of ADRs being reported, newer ADRs 
being reported, early detection of ADRs and allowing 
establishment of a strategy to prevent medication errors. [16]. 
In another article which analyzed previous literature on ADR 
reporting by patients, the authors concluded that patient 
reporting of suspected ADRs has more potential benefits than 
drawbacks. [17] 
 
In a report by WHO in 2000 entitled “Consumer reporting of 
adverse drug reactions” it is revealed that the benefits of 
incorporating consumers in ADRs reporting include the 
promotion of consumer rights and equity. Involving 
consumers could serve as a means of acknowledging that they 
have unique perspectives and experiences. As a result, 
healthcare organizations would in turn benefit from 
consumers’ involvement. In return, consumers will be driven 
by the motivation to benefit other medicine users. A study 
conducted by Medawar which attempted to compare the ADR 
reports from professionals and consumers related to the risk of 
dependence and suicidal behavior with paroxetine concluded 
that individual patient reports were much richer in their 
behavioral phenomena and feeling descriptions compared to 
the Yellow Card reports submitted by HCPs in the UK.[17] 
Potharaju asserts that ADR reports have the potential to be a 
quantitative indicator of quality and safety based on a research 
conducted by Agoritsas and co-workers in 2005 on patients 
being hospitalized [16]. 
 
Apart from that, consumer ADR reporting also helps to 
discover possible new ADRs that had not previously been 
reported by health professionals. This has been described in a 
review paper published by Blenkinsopp and co-workers in 
2007. The authors analyzed a total of eight published papers. 
They found that patients’ reports which are unfiltered by 
professional interpretation can bring new understanding about 
ADRs. This is because reports from users and their relatives 
regarding behavioral effects were far richer than that from 
professional reporters [18]. Commenting on the same paper 
published by Blenkinsopp in 2007, Alshakkain 
2013highlighted some important benefits of incorporating 
consumers in ADR reporting programs which can be listed as 
follows: 
a) provides regulatory authorities and clinical practice a 
new source of information 
b) discloses the drugs’ previously unknown effects  
c) earlier detection of ADRs due to direct reporting by 
consumers or patients 
d) alleviates the problem of under-reporting by 
increasing the number of reports 
e) provides details and information on patient’s quality 
of life 
f) alleviates the problem of lacking serious adverse 
effects in the reports written by health professionals  
g) provides useful information on ADRs as those 
provided by health professional, even though in a 
different style or expression 
h) encourages reports by the elderly people 
i) provides wider verities of reports on effects that 
have strong relationship with drugs. 
 
Current situation of consumer reporting of ADRs in 
Yemen 
 
Yemen lacks a proper pharmacovigilance program. Even 
though a regulatory body for drugs already exists (SBDMA), 
there have been no coordinated efforts among parties involved 
such as medical and pharmacy schools, pharmacovigilance 
centers and the pharmaceutical industry. The main reason for 
this is the lack of an active national drug policy. This might 
probably be the result of not having legislations and 
regulations which govern the importation and distribution of 
drugs. It is feared that the situation will worsen in the future if 
current stakeholders do not make efforts to rectify the problem 
[10]. 
 
The National Medicines Policy was established in 1998, sadly, 
it has not been implemented properly, where a formal 
implementation plan does not exist. There are no legal 
provisions in the Medicine Act that provide for 
pharmacovigilance activities as a part of Medicines 
Regulatory Authority mandate. Laws regarding the monitoring 
of ADRs do not exist. ADRs are not monitored systemically in 
any public health programm.[7] 
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Current situation of consumer reporting of ADRs in Nepal 
 
Currently, there is no provision for involving consumers in the 
existing pharmacovigilance program of Nepal. The drug act 
and the national drug policy of Nepal does not mention about 
pharmacovigilance, but the new national medicine policy 
which is under review will address pharmacovigilance. As 
mentioned by different authors, underreporting is still a major 
limitation hindering the success of the pharmacovigilance 
program in Nepal. Involving consumers in the program may 
be a good initiative for strengthening the existing system for 
pharmacovigilance. Currently, the program is focused on the 
reports collected from health care professionals. However the 
national drug regulatory authority, DDA is positive with 
regard to initiating consumer pharmacovigilance in the 
country as per verbal interactions of the author NJ with DDA 
officials.  
 
Current situation of consumer reporting of ADRs in 
Malaysia 
 
The history of ADR reporting by consumers or patients in 
Malaysia dates back to 2007. In the early years of its launch, 
the number of patients who submitted ADR reports was rather 
low, as indicated by the National Center. The reason for this is 
understandably similar as previously reported in research 
conducted in other countries, whereby pharmacists and other 
professionals tend to look at patients’ reports with a skeptical 
eye as they regard the patients as having limited knowledge 
and low awareness.[1] However, a research conducted in 11 
countries including Malaysia, concluded that the importance 
of giving the public the opportunity to report ADRs and the 
additional scientific value of the collected data is widely 
recognized by the countries who participated [19]. 
 
In a qualitative and quantitative study conducted at the 
UniversitiSains Malaysia, which attempted to compare the 
drug safety systems in Malaysia, Australia and Sweden, the 
author found that in terms of reporting requirements, report 
handling, resources spent and exchange of information in the 
environment were different. Australia and Sweden have a 
proper and more effective ADR reporting systems as well as 
consumer involvement compared to Malaysia.[1] The author 
also suggested that there is an urgent need for educational 
interventions among Health Care Practitioners (HCPs) in 
Malaysia due to their poor knowledge of pharmacovigilance. 
In addition, consumer knowledge about ADRs was also 
relatively low. For instance, out of the 500 general public 
surveyed, more than one-third did not know the definition of 
ADRs and more than half were unable to differentiate between 
side effects and ADRs. Almost 90% of both general public 
and HCPs agreed that consumer reporting would benefit the 
existing pharmacovigilance initiatives in Malaysia. The author 
has further concluded that in order to improve ADR reporting 
in Malaysia, the level of awareness of all stakeholders in the 
healthcare system needs to be improved. The consumers need 
to be educated about their medications, writing and filing valid 
reports and sending it to the proper authorities[1]. 
 
Challenges faced by consumers in reporting ADRs in 
developing countries 
 
In a research article entitled “Reporting Adverse Drug 
Reactions: Patients to be involved or not?” the author points 
out that there is a tendency for patient reporting to be viewed 
as politically driven rather than scientifically driven. Even 
though further examination based on data collected from 
patients’ report compared to those from HCPs showed no 
significant difference between them, patients are found to 
reflect more on their concerns about life threatening and 
significant disability cases. For instance, they were more 
likely to report symptoms related to delicate matters such as 
sexual dysfunction directly to the authorities rather than HCPs. 
They also are more likely to report symptoms related to their 
quality of life. This shows that there is some bias involved in 
ADRs reporting by consumers or patients. It is feared that 
databases generated from reports submitted by patients might 
be overlooked and not treated in a fair manner.[20] 
 
Another challenge faced by consumers in reporting ADRs is 
poor knowledge about ADRs. Patients’ knowledge about the 
definition of ADRs itself as well as how they report such cases 
and where they submit the cases may be poor. In a recent case 
study conducted in the state of Penang, Malaysia it was found 
that 65.6% of respondents reported that they were unaware 
about the existence of the ADR center established by the 
Ministry of Health. The author has pointed out that the result 
is in agreement with previous studies being conducted in the 
Philippines, Iran and Germany. In general the knowledge of 
general public, pharmacists as well as HCPs in university 
hospitals about ADRs is poor.[1] 
 
Addressing the medium through which an ADR can be 
reported by consumers, a study in 11 countries including 
Australia, Canada, Denmark, Netherlands, New Zealand, 
Norway, Malaysia, Philippines, Sweden, UK and USA, found 
that only five countries offer the facility to file a report via 
phone, electronic forms and paper forms namely Australia, 
Canada, New Zealand, UK and USA. As for developing 
countries such as Malaysia and the Philippines, consumers 
would only be able to file their report either via telephone or 
paper forms. This restriction of methods through which a 
report can be filed might be the reason why consumer 
reporting of ADRs in these two countries is still relatively 
very low. In both countries, the percentage of consumer ADR 
reports is well below 10 percent [18]. 
 
In the same report, perhaps the answer to the question why the 
level of knowledge among general public, particularly in 
developing countries is still very low is the lack of funding for 
campaigns to make the public aware of the possibility that 
consumers can report ADRs as well as the reporting scheme. 
In Malaysia, the Ministry of Health remains the sole body 
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which provides funds to promote consumer reporting by 
putting it on a website, via posters that they put upin hospitals 
and flyers that they give to patients. These efforts are still 
insufficient to increase the level of awareness and knowledge 
among the general public on ADR reporting. It is hoped that 
other parties such as NGOs would work together to improve 
the pharmacovigilance initiatives in the country.[20] 
 
In Yemen, the major problem faced by consumers is the poor 
pharmacovigilance system. Currently, Yemen is way behind 
other developing countries in terms of improving the 
effectiveness of the ADR reporting system. Another 
contributing factor is the lack of nationwide coverage of 
pharmacovigilance centers, as well as hospitals. This might 
probably originate from the lack of legislation and clear policy 
on pharmacovigilance. Studies have found that 60% of all 
imported medicines in Yemen originated through illegal 
channels. [10] .As a result, the occurrence of fake medicine 
and drugs is rampant which poses serious threat to the health 
of the public. 
 
In addition, the lack of ADR monitoring in Yemen might lead 
consumers to believe that their reports may not be acted upon 
and this may eventually deter them from filing reports. This, 
added with the high illiteracy of the Yemeni population, might 
make it impossible to establish a proper and effective ADRs 
reporting system in the country [10] 
 
Similarly, Nepal also being a developing country has many 
hurdles and obstacles for an effective pharmacovigilance 
program. Political instability and lack of good governance 
may be another hindering factor for proper development of 
such programs. Funding is another limitation. Till now, WHO 
has been helping financially with pharmacovigilance program 
in Nepal. Department of drug administration is the national 
center for pharmacovigilance and the seven regional centers 
are not having a nationwide coverage. Lack of human 
resources dedicated for pharmacovigilance program is another 
major constraint. Consumers are not yet involved in reporting 
ADRs till date. Pharmacovigilance program is still in its 
infancy in Nepal and there is a long way to go for a systematic 
and properly functioning system.   
 
Realizing the potential benefits of consumer reporting as well 
as the motivation to establish a proper and effective 
pharmacovigilance program throughout the country, a pilot 
study has been carried out in Malaysia to test the viability of 
the newly formulated system. Now, more than 6 years after 
the first pilot study had commenced, a healthy increase of 
ADR reporting was observed. The number of ADRs being 
reported in the country in the year 2010 was 7079, a 
significant 21% increase compared to the previous year. 
Therefore, the future looks bright for consumer 
pharmacovigilance in Malaysia. 
 For Yemen and Nepal, however, much still needs to 
be done. The foremost is to have proper legislation backed by 
appropriate policies with proper implementation plans. The 
illiteracy rate needs to be addressed in a holistic and thorough 
manner. For this to be a success, all stakeholders, especially 
the government must work as a team and channel their energy 
and focus towards establishing a comprehensive 
pharmacovigilance program. 
Conclusion 
 
Having a proper and effective ADR reporting system is crucial 
for every country as it could reduce potential health hazards 
such as morbidity and mortality. The economic burden 
associated with these hazards can also be alleviated. Even 
though spontaneous and voluntary ADR reporting system has 
been the mainstay since its inception, the status quo is now 
changing due to increased awareness of all stakeholders on the 
need to incorporate consumers into the existing reporting 
system. This may partly alleviate the problem of under-
reporting which has plagued the system. 
Based on the facts presented above, it is clear that consumer 
reporting is the way forward to attain a proper and effective 
pharmacovigilance program that can address the very 
fundamental task of alleviating morbidity and mortality rates, 
as well as reducing the economic burden. 
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